

## MIPS #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier

Electronic health records (EHRs) collect and organize notes, medication lists, and patient information using various formats. With providers also documenting this information in unique ways, this can potentially cause confusion and an increased timeline for measure mapping with DataDerm. This tip sheet can help you manage reporting requirements for performance measures and streamline standard documentation practices to allow seamless data pull into DataDerm.

The DataDerm team will work with you to connect DataDerm with your EHR to extract data. To make the process as smooth as possible, it helps to document key elements of patient care. DataDerm cannot read scanned images of any kind, including scanned images for labs, letters to physicians, pathology reports, follow-up plans, and dates. If you have scanned images with information needed for your measures, please add a note in your chart with the date and required patient information for this data to be accurately collected.

This tip sheet can assist paper-based practices in standardizing documentation practices. Keeping notes in the patient's paper chart of all documentation requirements will assist you when reporting for this measure.

### MIPS 337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier

For all patients, document the following in your notes:

- Eligible diagnosis and encounter codes:
  - ICD-10 diagnosis codes for:
    - Psoriasis (L40.0, L40.1, L40.2, L40.3, L40.4, L40.8, L40.9),
    - Psoriatic arthritis (L40.50, L40.51, L40.52, L40.53, L40.54, L40.59), or
    - Rheumatoid arthritis (M05.10, M05.111, M05.112, M05.119, M05.121, M05.122, M05.129, M05.131, M05.132, M05.139, M05.141, M05.142, M05.149, M05.151, M05.152, M05.159, M05.161, M05.162, M05.169, M05.171, M05.172, M05.179, M05.19, M05.20, M05.211, M05.212, M05.219, M05.221, M05.222, M05.229, M05.231, M05.232, M05.239, M05.241, M05.242, M05.249, M05.251, M05.252, M05.259, M05.261, M05.262, M05.269, M05.271, M05.272, M05.279, M05.29, M05.30, M05.311, M05.312, M05.319, M05.321, M05.322, M05.329, M05.331, M05.332, M05.339, M05.341, M05.342, M05.349, M05.351, M05.352, M05.359, M05.361, M05.362, M05.369, M05.371, M05.372, M05.379, M05.39, M05.40, M05.411, M05.412, M05.419, M05.421, M05.422, M05.429, M05.431, M05.432, M05.439, M05.441, M05.442, M05.449, M05.451, M05.452, M05.459, M05.461, M05.462, M05.469, M05.471, M05.472, M05.479, M05.49, M05.50, M05.511, M05.512, M05.519, M05.521, M05.522, M05.529, M05.531, M05.532, M05.539, M05.541, M05.542, M05.549, M05.551, M05.552, M05.559, M05.561, M05.562, M05.569, M05.571, M05.572, M05.579, M05.59, M05.60, M05.611, M05.612, M05.619, M05.621, M05.622, M05.629, M05.631, M05.632, M05.639, M05.641, M05.642, M05.649, M05.651, M05.652, M05.659, M05.661, M05.662, M05.669, M05.671, M05.672, M05.679, M05.69, M05.70, M05.711, M05.712, M05.719, M05.721, M05.722, M05.729, M05.731, M05.732, M05.739, M05.741, M05.742, M05.749, M05.751, M05.752, M05.759, M05.761, M05.762, M05.769, M05.771, M05.772, M05.779, M05.79, M05.80, M05.811, M05.812, M05.819, M05.821, M05.822, M05.829, M05.831, M05.832, M05.839, M05.841, M05.842, M05.849, M05.851, M05.852, M05.859, M05.861,

For more information, contact the American Academy of Dermatology:

WEBSITE: [aad.org](http://aad.org)

© by the American Academy of Dermatology and the American Academy of Dermatology Association.  
"All Rights Reserved." Reproduction or republication is strictly prohibited without prior written permission. The Measure is copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices) without obtaining approval from AAD.



AMERICAN ACADEMY of  
DERMATOLOGY | ASSOCIATION

## MIPS #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier

M05.862, M05.869, M05.871, M05.872, M05.879, M05.89, M05.9, M06.00, M06.011, M06.012, M06.019, M06.021, M06.022, M06.029, M06.031, M06.032, M06.039, M06.041, M06.042, M06.049, M06.051, M06.052, M06.059, M06.061, M06.062, M06.069, M06.071, M06.072, M06.079, M06.08, M06.09, M06.1, M06.20, M06.211, M06.212, M06.219, M06.221, M06.222, M06.229, M06.231, M06.232, M06.239, M06.241, M06.242, M06.249, M06.251, M06.252, M06.259, M06.261, M06.262, M06.269, M06.271, M06.272, M06.279, M06.28, M06.29, M06.30, M06.311, M06.312, M06.319, M06.321, M06.322, M06.329, M06.331, M06.332, M06.339, M06.341, M06.342, M06.349, M06.351, M06.352, M06.359, M06.361, M06.362, M06.369, M06.371, M06.372, M06.379, M06.38, M06.39, M06.80, M06.811, M06.812, M06.819, M06.821, M06.822, M06.829, M06.831, M06.832, M06.839, M06.841, M06.842, M06.849, M06.851, M06.852, M06.859, M06.861, M06.862, M06.869, M06.871, M06.872, M06.879, M06.88, M06.89, M06.9)

- CPT or HCPCS codes for the patient encounter during measurement period (99201, 99202, 99203, 99204, 99205, 99212, 99213, 99214, 99215, 99241, 99242, 99243, 99244, 99245, G0402)
- Code G9506 - Biologic immune response modifier prescribed
  - List name of biologic (see medication list below) and/or identify biologics prescribed for treatment of psoriasis, psoriatic arthritis, or rheumatoid arthritis
  - List the name of the provider that ordered the biologic in notes or state that biologics were ordered by another provider
  - Document date of when patient began treatment.
- Document proof of negative tuberculosis (TB) screening test before beginning biologic treatment.
  - Record date of TB screening test results
  - Results of TB screening test (positive or negative)
    - If positive, document that provider has managed positive TB screen with further evidence/documentation that TB is not active, confirmed via radiographic imaging (i.e. chest x-ray, CT) prior to treatment with a biologic immune response modifier
- If screening results are not documented, note reason(s). If applicable, include:
  - Patient did not return for Mantoux (PPD) skin test evaluation

### Additional Tips:

- Collect **once per performance period** for patients seen with psoriasis and/or psoriatic arthritis and/or rheumatoid arthritis during the performance period.
- See measure specifications for additional codes that can assist in seamless measure mapping from your EHR to DataDerm, if applicable (e.g. G9359).
- The provider reporting or being evaluated for the measure must see patient with eligible diagnosis **AND** prescribe the biologic immune response modifier.
- GQ, GT, 95, POS 02 telehealth modifiers make cases ineligible.

### Updates:

- Added Denominator Coding, ICD-10-CM: M05.622
- TB screening should occur prior to treatment with a biologic immune response modifier, **not** annually.
- Skyrizi (risankizumab-rzaa) has been added to the "Medications Applicable to MIPS 337" list.

For more information, contact the American Academy of Dermatology:

WEBSITE: [aad.org](http://aad.org)

© by the American Academy of Dermatology and the American Academy of Dermatology Association.  
"All Rights Reserved." Reproduction or republication is strictly prohibited without prior written permission. The Measure is copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices) without obtaining approval from AAD.



AMERICAN ACADEMY of  
DERMATOLOGY | ASSOCIATION

## MIPS #337: Psoriasis: Tuberculosis (TB) Prevention for Patients with Psoriasis, Psoriatic Arthritis and Rheumatoid Arthritis on a Biological Immune Response Modifier

### Medications Applicable to MIPS 337

Brand name	Chemical name	Mechanism of action/Type of biologic
Orencia	abatacept	Blocks T cell activation
Rituxan	rituximab	CD 20 directed antibody
Kineret	anakinra	Interleukin IL1 inhibitors
Actemra	tocilizumab	IL-6 inhibitor
Kevzara	sarilumab	IL-6 inhibitor
Stelara	ustekinumab	IL-12 and IL-23 inhibitors
Cosentyx	secukinumab	IL-17 inhibitors
Siliq	brodalumab	IL-17 inhibitors
Taltz	Ixekizumab	IL-17 inhibitors
Tremfya	guselkumab	IL-23 inhibitors
Skyrizi	risankizumab-rzaa	IL-23 inhibitors
Ilumya	tidrakizumab	Selective IL-23p19 inhibitors
Amjevita	adalimumab-atto	TNF-alpha inhibitors
Cimzia	certolizumab	TNF-alpha inhibitors
Cyltezo	adalimumab-adbm	TNF-alpha inhibitors
Enbrel	etanercept	TNF-alpha inhibitors
Erelzi	etanercept-szsz	TNF-alpha inhibitors
Humira	adalimumab	TNF-alpha inhibitors
Inflectra	infliximab-dyyb	TNF-alpha inhibitors
Remicade	infliximab	TNF-alpha inhibitors
Renflexis	infliximab-abda	TNF-alpha inhibitors
Simponi & Simponi Aria	golimumab	TNF-alpha inhibitors

For more information, contact the American Academy of Dermatology:

WEBSITE: [aad.org](http://aad.org)

© by the American Academy of Dermatology and the American Academy of Dermatology Association.  
"All Rights Reserved." Reproduction or republication is strictly prohibited without prior written permission. The Measure is copyrighted but can be reproduced and distributed, without modification, for noncommercial purposes (eg, use by healthcare providers in connection with their practices) without obtaining approval from AAD.



AMERICAN ACADEMY of  
DERMATOLOGY | ASSOCIATION